AqueSys, a life sciences firm focusing on developing treatments for glaucoma, has secured $43.6m in its series D round, according to a SEC filing. Backers in the round include venture firms Accuitive Medical Ventures, Longitude Capital, Rho Ventures, and SV Life Sciences. Private equity firm the Carlyle Group also backed the round. All the backers…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
